Added to YB: 2026-02-04
Pitch date: 2026-02-02
IDXG [bullish]
Interpace Biosciences, Inc.
-5.76%
current return
Author Info
The Micro-Capo is a blog where I share news and articles on companies I like or own. Sign up for the newsletter.
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
Market Cap
$52.3M
Pitch Price
$1.91
Price Target
4.50 (+150%)
Dividend
N/A
EV/EBITDA
9.51
P/E
17.42
EV/Sales
1.27
Sector
Health Care Providers and Services
Category
turnaround
The Micro-Capo | January 2026 - Interpace Biosciences, Inc.
IDXG (holding update): Thyroid diagnostics biz growing post-PancraGEN exit. Capital structure simplified - all preferred converted to common, debt eliminated. Sets stage for Nasdaq uplisting. $7-8M EBITDA by 2027 at 7-8x EV/EBITDA = $55-65M enterprise value, $3.50-$4.50/share target. Clean balance sheet, execution risk down.
Read full article (1 min)